Money Is Moving

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Public market insider buying at Valeo Pharma (C:VPH)

Updated Thursday Jun 23, 2022 02:03 AM EDT

100079 Canada Inc., a 10% Holder, acquired 299,500 Common Shares Class A on a direct ownership basis at prices ranging from $0.580 to $0.619 between June 20th, 2022 and June 21st, 2022. This represents a $181,321 investment into the company's shares and an account share holdings change of 2.6%.

Valeo Pharma is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Valeo Pharma Inc. is a Canada-based specialty pharmaceutical company. The Company acquires or in-licenses brand and hospital specialty products for sale in Canada. The Company is focused on four therapeutic areas, which includes respiratory, oncology, specialty products and neurology. Its respiratory product is Enerzair breezhaler and Atectura breezhaler; its oncology product is Yondelis; its specialty product includes Redesca, Ametop Gel, and M-Eslon and its neurology product is Onstryv. The Company has eight marketed brands and four additional products. Its wholly owned subsidiary is VPI Pharmaceuticals Inc.(VPI). Valeo Pharma Inc. (VPH) has a high amount of executive buying compared to its small-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $181,321.

INK Edge Outlook

6 months ago
1 year ago
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at
Two-week free trial for first time users.
Go to Valeo Pharma Inc. (VPH)'s company page

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).

Comment On!

No Comments


Search (past week) for $VPH.CA

  • No tweets found


Valeo Pharma Inc.

  • Symbol not found.